JAZZ
Jazz Pharmaceuticals plc NASDAQ Listed Jun 1, 2007$226.95
Mkt Cap $14.2B
52w Low $97.50
97.4% of range
52w High $230.40
50d MA $192.56
200d MA $157.94
P/E (TTM)
-34.7x
EV/EBITDA
132.8x
P/B
2.9x
Debt/Equity
1.3x
ROE
-8.2%
P/FCF
8.0x
RSI (14)
—
ATR (14)
—
Beta
0.23
50d MA
$192.56
200d MA
$157.94
Avg Volume
956.2K
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Waterloo Exchange · Dublin 4 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 4.67 | 6.34 | +35.8% | 212.26 | +7.4% | +7.7% | +6.9% | — | — | — | — |
| Feb 24, 2026 | AMC | 6.52 | 6.64 | +1.8% | 173.83 | +3.5% | +13.2% | +8.7% | +9.3% | +9.6% | +7.4% | — |
| Nov 5, 2025 | AMC | 5.95 | 8.13 | +36.6% | 137.22 | +3.7% | -2.3% | -4.4% | -2.9% | -0.1% | -0.4% | — |
| Aug 5, 2025 | AMC | -6.12 | -8.25 | -34.8% | 113.20 | -5.0% | -6.4% | -1.0% | -1.7% | -2.2% | +0.1% | — |
| May 6, 2025 | AMC | 4.51 | 1.68 | -62.7% | 111.17 | -5.1% | -8.8% | -11.5% | -12.0% | -6.8% | -7.4% | — |
| Feb 25, 2025 | AMC | 5.83 | 6.60 | +13.2% | 139.67 | +0.6% | +3.2% | +2.6% | +2.8% | +0.4% | -0.5% | — |
| Nov 6, 2024 | AMC | 5.47 | 6.61 | +20.8% | 111.55 | +4.8% | +6.8% | +10.8% | +14.0% | +14.5% | +14.4% | — |
| Jul 31, 2024 | AMC | 4.68 | 5.30 | +13.2% | 110.25 | +2.6% | +3.7% | +2.7% | +1.2% | +1.0% | +1.8% | — |
| May 1, 2024 | AMC | 4.14 | 2.68 | -35.3% | 110.31 | -4.7% | -0.9% | -0.3% | -0.4% | +0.8% | +0.4% | — |
| Feb 28, 2024 | AMC | 5.26 | 5.02 | -4.6% | 129.70 | -3.2% | -8.3% | -8.4% | -9.4% | -8.7% | -9.6% | — |
| Nov 8, 2023 | AMC | 4.90 | 4.84 | -1.2% | 128.24 | +0.2% | -9.1% | -6.3% | -4.9% | -2.7% | -2.2% | — |
| Aug 9, 2023 | AMC | 4.46 | 4.51 | +1.1% | 133.00 | +4.3% | +1.6% | +4.8% | +5.3% | +5.3% | +3.8% | — |
| May 10, 2023 | AMC | 4.26 | 3.95 | -7.3% | 136.53 | +0.3% | +0.4% | -0.6% | -1.4% | -4.0% | -3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $199.03 | $200.74 | +0.9% | +1.7% | +0.5% | -1.3% | +1.1% | +2.5% |
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $203.42 | $206.34 | +1.4% | -0.4% | -2.2% | -0.5% | -1.7% | -3.4% |
| Mar 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $180.45 | $180.72 | +0.1% | +0.7% | +0.1% | +1.0% | +2.5% | +4.8% |
| Feb 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $173.83 | $180.00 | +3.5% | +13.2% | +8.7% | +9.3% | +9.6% | +7.4% |
| Feb 25 | RBC Capital | Maintains | Outperform → Outperform | — | $173.83 | $180.00 | +3.5% | +13.2% | +8.7% | +9.3% | +9.6% | +7.4% |
| Feb 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $173.83 | $180.00 | +3.5% | +13.2% | +8.7% | +9.3% | +9.6% | +7.4% |
| Feb 25 | BofA Securities | Maintains | Buy → Buy | — | $173.83 | $180.00 | +3.5% | +13.2% | +8.7% | +9.3% | +9.6% | +7.4% |
| Jan 12 | Truist | Maintains | Buy → Buy | — | $161.13 | $162.63 | +0.9% | +1.6% | +0.8% | +6.0% | +6.2% | +5.1% |
| Jan 12 | Needham | Maintains | Buy → Buy | — | $161.13 | $162.63 | +0.9% | +1.6% | +0.8% | +6.0% | +6.2% | +5.1% |
| Dec 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $162.26 | $165.35 | +1.9% | +1.7% | +1.6% | +3.2% | +4.5% | +4.6% |
| Nov 24 | UBS | Downgrade | Buy → Neutral | — | $176.93 | $174.89 | -1.2% | +2.2% | +1.8% | -0.0% | -0.2% | -2.7% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $170.09 | $170.09 | +0.0% | +6.1% | +3.5% | +3.3% | +4.0% | +6.4% |
| Nov 18 | Baird | Maintains | Outperform → Outperform | — | $170.09 | $170.09 | +0.0% | +6.1% | +3.5% | +3.3% | +4.0% | +6.4% |
| Nov 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $170.09 | $170.09 | +0.0% | +6.1% | +3.5% | +3.3% | +4.0% | +6.4% |
| Nov 17 | RBC Capital | Maintains | Outperform → Outperform | — | $141.07 | $168.00 | +19.1% | +20.6% | +28.0% | +24.8% | +24.6% | +25.4% |
| Nov 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $141.07 | $168.00 | +19.1% | +20.6% | +28.0% | +24.8% | +24.6% | +25.4% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $137.22 | $142.24 | +3.7% | -2.3% | -4.4% | -2.9% | -0.1% | -0.4% |
| Oct 27 | JP Morgan | Maintains | Overweight → Overweight | — | $138.53 | $140.00 | +1.1% | +0.6% | -0.3% | -2.0% | -1.6% | -0.6% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $136.06 | $137.18 | +0.8% | -0.9% | +1.1% | +1.8% | +1.6% | +1.8% |
| Sep 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $129.40 | $129.80 | +0.3% | +0.1% | -1.2% | -1.9% | -0.3% | +1.9% |
| Aug 29 | Goldman Sachs | Maintains | Buy → Buy | — | $126.13 | $126.06 | -0.1% | +1.3% | +2.8% | +4.4% | +1.5% | +2.7% |
| Aug 28 | Truist | Maintains | Buy → Buy | — | $124.43 | $124.43 | +0.0% | +1.4% | +2.7% | +4.2% | +5.9% | +2.9% |
| Aug 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $124.43 | $124.43 | +0.0% | +1.4% | +2.7% | +4.2% | +5.9% | +2.9% |
| Aug 28 | Needham | Maintains | Buy → Buy | — | $124.43 | $124.43 | +0.0% | +1.4% | +2.7% | +4.2% | +5.9% | +2.9% |
| Aug 28 | RBC Capital | Maintains | Outperform → Outperform | — | $124.43 | $124.43 | +0.0% | +1.4% | +2.7% | +4.2% | +5.9% | +2.9% |
| Aug 20 | Needham | Maintains | Buy → Buy | — | $119.20 | $119.73 | +0.4% | -0.1% | +1.1% | +3.3% | +4.5% | +4.9% |
| Aug 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $113.20 | $107.55 | -5.0% | -6.4% | -1.0% | -1.7% | -2.2% | +0.1% |
| Jul 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $112.65 | $112.17 | -0.4% | +3.3% | +4.2% | +4.8% | +5.0% | +4.2% |
| Jun 11 | Needham | Maintains | Buy → Buy | — | $113.00 | $113.18 | +0.2% | -2.2% | -2.4% | -4.0% | -3.0% | -5.3% |
| Jun 3 | Needham | Maintains | Buy → Buy | — | $108.29 | $108.81 | +0.5% | +1.9% | +1.1% | +0.5% | +2.6% | +3.3% |
| May 7 | Needham | Maintains | Buy → Buy | — | $111.17 | $105.51 | -5.1% | -8.8% | -11.5% | -12.0% | -6.8% | -7.4% |
| May 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $111.17 | $105.51 | -5.1% | -8.8% | -11.5% | -12.0% | -6.8% | -7.4% |
| May 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $111.17 | $105.51 | -5.1% | -8.8% | -11.5% | -12.0% | -6.8% | -7.4% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $111.17 | $105.51 | -5.1% | -8.8% | -11.5% | -12.0% | -6.8% | -7.4% |
| May 7 | Baird | Maintains | Outperform → Outperform | — | $111.17 | $105.51 | -5.1% | -8.8% | -11.5% | -12.0% | -6.8% | -7.4% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $110.12 | $108.04 | -1.9% | -7.3% | -8.7% | -7.6% | -6.5% | -7.8% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $138.81 | $138.19 | -0.4% | -1.0% | -1.4% | -3.3% | -2.0% | -0.6% |
| Mar 7 | UBS | Upgrade | Neutral → Buy | — | $136.45 | $139.18 | +2.0% | +1.7% | +0.7% | +0.3% | -1.7% | -0.3% |
| Mar 6 | Truist | Maintains | Buy → Buy | — | $140.23 | $138.27 | -1.4% | -2.7% | -1.0% | -2.0% | -2.4% | -4.3% |
| Mar 5 | Needham | Maintains | Buy → Buy | — | $138.95 | $139.28 | +0.2% | +0.9% | -1.8% | -0.1% | -1.1% | -1.5% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $144.17 | $142.51 | -1.2% | -0.6% | -0.4% | -2.7% | -3.6% | -2.7% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $139.67 | $140.50 | +0.6% | +3.2% | +2.6% | +2.8% | +0.4% | -0.5% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $139.67 | $140.50 | +0.6% | +3.2% | +2.6% | +2.8% | +0.4% | -0.5% |
| Feb 26 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $139.67 | $140.50 | +0.6% | +3.2% | +2.6% | +2.8% | +0.4% | -0.5% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $139.67 | $140.50 | +0.6% | +3.2% | +2.6% | +2.8% | +0.4% | -0.5% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $139.67 | $140.50 | +0.6% | +3.2% | +2.6% | +2.8% | +0.4% | -0.5% |
| Feb 13 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $135.44 | $137.65 | +1.6% | +1.0% | -1.1% | -0.0% | -0.4% | +0.9% |
| Dec 12 | RBC Capital | Maintains | Outperform → Outperform | — | $120.72 | $123.83 | +2.6% | +2.4% | +1.9% | +3.7% | +1.5% | +0.8% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $120.72 | $123.83 | +2.6% | +2.4% | +1.9% | +3.7% | +1.5% | +0.8% |
| Dec 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $120.72 | $123.83 | +2.6% | +2.4% | +1.9% | +3.7% | +1.5% | +0.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | COZADD BRUCE CDir | — | Sell | 6,000 | $203.33 | $1.2M | 378,682 | +7.68% | — |
Data updated apr 25, 2026 4:40pm
· Source: massive.com